Dexilant Solutab is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 28 US drug patents filed in 2016. Out of these, 7 drug patents are active and 21 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 10, 2029. Details of Dexilant Solutab's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US6664276 | Benzimidazole compound crystal |
Jan, 2023
(1 year, 10 months ago) |
Expired
|
| US9145389 | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) |
Expired
|
| US6462058 | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) |
Expired
|
| US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(4 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9241910 | Orally-disintegrating solid preparation |
Mar, 2029
(4 years from now) | Active |
|
US8871273 (Pediatric) | Method for producing granules |
Jul, 2028
(3 years from now) | Active |
| US8871273 | Method for producing granules |
Jan, 2028
(3 years from now) | Active |
|
US8461187 (Pediatric) | Multiple PPI dosage form |
Jul, 2026
(1 year, 6 months from now) | Active |
| US9011926 | Method for producing granules |
Feb, 2026
(1 year, 1 month from now) | Active |
| US9238029 | Multiple PPI dosage form |
Jan, 2026
(1 year, 20 days from now) | Active |
| US8461187 | Multiple PPI dosage form |
Jan, 2026
(1 year, 20 days from now) | Active |
|
US8784885 (Pediatric) | Controlled release preparation |
Apr, 2024
(8 months ago) |
Expired
|
| US8784885 | Controlled release preparation |
Oct, 2023
(1 year, 2 months ago) |
Expired
|
|
US6664276 (Pediatric) | Benzimidazole compound crystal |
Jul, 2023
(1 year, 4 months ago) |
Expired
|
|
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(4 years ago) |
Expired
|
|
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) |
Expired
|
|
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) |
Expired
|
| US6939971 | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) |
Expired
|
|
US6328994 (Pediatric) | Orally disintegrable tablets |
Nov, 2019
(5 years ago) |
Expired
|
|
US6238994 (Pediatric) | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(5 years ago) |
Expired
|
|
US7875292 (Pediatric) | Orally disintegrable tablets |
Nov, 2019
(5 years ago) |
Expired
|
|
US7431942 (Pediatric) | Orally disintegrable tablets |
Nov, 2019
(5 years ago) |
Expired
|
| US7431942 | Orally disintegrable tablets |
May, 2019
(5 years ago) |
Expired
|
| US7875292 | Orally disintegrable tablets |
May, 2019
(5 years ago) |
Expired
|
| US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(5 years ago) |
Expired
|
| US6328994 | Orally disintegrable tablets |
May, 2019
(5 years ago) |
Expired
|
|
US7399485 (Pediatric) | Rapidly Disintegrable solid preparation |
Nov, 2018
(6 years ago) |
Expired
|
| US7399485 | Rapidly Disintegrable solid preparation |
May, 2018
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dexilant Solutab's patents.
Latest Legal Activities on Dexilant Solutab's Patents
Given below is the list of recent legal activities going on the following patents of Dexilant Solutab.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 06 Nov, 2023 | US9145389 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jun, 2023 | US9241910 |
| Maintenance Fee Reminder Mailed Critical | 22 May, 2023 | US9145389 |
| Expire Patent Critical | 27 Feb, 2023 | US7875292 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2022 | US9011926 |
| Maintenance Fee Reminder Mailed Critical | 12 Sep, 2022 | US7875292 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Mar, 2022 | US8871273 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jan, 2022 | US8784885 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Dec, 2020 | US8461187 |
| Expire Patent Critical | 09 Nov, 2020 | US7431942 (Litigated) |
Several oppositions have been filed on Dexilant Solutab's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Dexilant Solutab's generic, the next section provides detailed information on ongoing and past EP oppositions related to Dexilant Solutab patents.
Dexilant Solutab's Oppositions Filed in EPO
Dexilant Solutab has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 02, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP00937235A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP10175046A | Jun, 2016 | Aechter, Bernd | Patent maintained as amended |
| EP03754116A | Dec, 2013 | Sanovel IIaç San. ve Tic. A.S. | Patent maintained as amended |
| EP00937235A | Jan, 2009 | Teva Pharmaceutical Industries Ltd. | Opposition procedure closed |
US patents provide insights into the exclusivity only within the United States, but Dexilant Solutab is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dexilant Solutab's family patents as well as insights into ongoing legal events on those patents.
Dexilant Solutab's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dexilant Solutab's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 10, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dexilant Solutab Generic API suppliers:
Dexlansoprazole is the generic name for the brand Dexilant Solutab. 3 different companies have already filed for the generic of Dexilant Solutab, with Endo Operations having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dexilant Solutab's generic
Alternative Brands for Dexilant Solutab
Dexilant Solutab which is used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis., has several other brand drugs in the same treatment category and using the same active ingredient (Dexlansoprazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Takeda Pharms Usa |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dexlansoprazole, Dexilant Solutab's active ingredient. Check the complete list of approved generic manufacturers for Dexilant Solutab
About Dexilant Solutab
Dexilant Solutab is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis. Dexilant Solutab uses Dexlansoprazole as an active ingredient. Dexilant Solutab was launched by Takeda Pharms Usa in 2016.
Approval Date:
Dexilant Solutab was approved by FDA for market use on 26 January, 2016.
Active Ingredient:
Dexilant Solutab uses Dexlansoprazole as the active ingredient. Check out other Drugs and Companies using Dexlansoprazole ingredient
Treatment:
Dexilant Solutab is used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis.
Dosage:
Dexilant Solutab is available in tablet, orally disintegrating, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | Discontinued | ORAL |